Pain caused by MS. Multiple sclerosis
Conditions
Interventions
Intervention 1: Intervention group: Half of the patients in the lacosamide group received lacosamide tablets 100 mg twice a day in the first week, and from the second week, the dose was prescribed as
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adults over the age of 18 and suffering from MS with moderate to high MS pain complaint
Exclusion criteria
Exclusion criteria: Severe depression or suicidal thoughts Thyroid disorders Severe anemia (Hb<9g/dl) Breast feeding or pregnancy History of cerebral ischemia or cardiovascular disease Having kidney failure (creatinine clearance less than 30 ml/min) Existence of an MS attack during the past month Concomitant use of drugs effective in pain control during the last month History of abuse of drugs, psychotropic substances and alcohol History of liver failure History of cardiac arrhythmia or simultaneous use of drugs affecting heart rhythm Failure to receive corticosteroid pulse within a month before the starting of study Absence of a history of structural disorder affecting the occurrence of pain such as discopathy and other disease affecting the occurrence of neuropathic pain( diabetes, trigeminal neuralgia,...)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intensity of pain caused by MS. Timepoint: Weeks 0-4-8-12. Method of measurement: Brief pain index (BPI).;Intensity of pain caused by MS. Timepoint: Weeks 0-4-8-12. Method of measurement: NPSI (Neuropathic Pain Symptom Inventory ).;The overall improvement rate of MS patients after taking lacosamide. Timepoint: Weeks 0-4-8-12. Method of measurement: Patient Global Impression of Change (PGIC).;The safety of lacosamide in improving pain caused by MS. Timepoint: Weekly. Method of measurement: Patient tolerability. | — |
Secondary
| Measure | Time frame |
|---|---|
| Determining the improvement in function and quality of life of patients with MS following the use of lacosamide. Timepoint: Weeks 0-8-12. Method of measurement: Item Short Form Survey (SF-36). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMonireh Ghazaeian
Mazandaran University of Medical Sciences
Outcome results
None listed